Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1–Infected Patients
暂无分享,去创建一个
B. Gazzard | M. Boffito | D. Back | A. Pozniak | M. Nelson | L. Dickinson | G. Moyle | A. Hill | C. Higgs | C. Fletcher
[1] R. Paredes,et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. , 2003, The Journal of infectious diseases.
[2] Z. Fox,et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. , 2003, The Journal of infectious diseases.
[3] C. Kovacs,et al. Clinical Impact of Double Protease Inhibitor Boosting with Lopinavir/Ritonavir and Amprenavir as Part of Salvage Antiretroviral Therapy , 2003, HIV clinical trials.
[4] W. Rozenbaum,et al. High Variability of Plasma Drug Concentrations in Dual Protease Inhibitor Regimens , 2003, Antimicrobial Agents and Chemotherapy.
[5] C. Goujard,et al. Steady-State Pharmacokinetics of Amprenavir Coadministered with Ritonavir in Human Immunodeficiency Virus Type 1-Infected Patients , 2003, Antimicrobial Agents and Chemotherapy.
[6] G. Plosker,et al. Saquinavir: a review of its use in boosted regimens for treating HIV infection. , 2003, Drugs.
[7] R. Shafer,et al. Drug resistance mutations in HIV-1. , 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[8] Victor DeGruttola,et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. , 2002, JAMA.
[9] B. Sadler,et al. Pharmacokinetic Modeling and Simulations of Interaction of Amprenavir and Ritonavir , 2002, Antimicrobial Agents and Chemotherapy.
[10] C. Leport,et al. Amprenavir Inhibitory Quotient and Virological Response in Human Immunodeficiency Virus-Infected Patients on an Amprenavir-Containing Salvage Regimen without or with Ritonavir , 2002, Antimicrobial Agents and Chemotherapy.
[11] S. Mauss,et al. Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir? , 2002, AIDS.
[12] R. Haubrich,et al. Pharmacokinetic Study of Human Immunodeficiency Virus Protease Inhibitors Used in Combination with Amprenavir , 2001, Antimicrobial Agents and Chemotherapy.
[13] B. Sadler,et al. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers , 2001, AIDS.
[14] J. Polli,et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[15] M. Saag,et al. Safety and Pharmacokinetics of Once-Daily Regimens of Soft-Gel Capsule Saquinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Negative Adults , 2000, Antimicrobial Agents and Chemotherapy.
[16] D. Greenblatt,et al. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole , 2000, European Journal of Clinical Pharmacology.
[17] R Rode,et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. , 1999, AIDS.
[18] C. Decker,et al. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. , 1998, Journal of pharmaceutical sciences.
[19] J. Leonard,et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir * , 1998, Clinical pharmacology and therapeutics.
[20] B. Sadler,et al. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. , 1996, Antiviral research.